Entegrion to develop blood product for U.S. Navy

08/26/2011 | MedCityNews.com

North Carolina biotech firm Entegrion is set to receive $9.84 million from the Navy for the development of a single blood product that has the potential to save lives on the battlefield. The product will combine two experimental blood products: Resusix, a freeze-dried human plasma designed to serve as an alternative to fresh-frozen plasma, and Stasix, a freeze-dried product based on blood platelets.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ